Építés alatt – nem éles oldal
Belépés

685 open Áttétes emlőrák trials worldwide. Travel and costs are your own unless the study pays them; ask the study team first.

OrszágOpen trials
Kína225
Egyesült Államok223
Franciaország83
Spanyolország74
Olaszország70
All other countries

The same trial often runs in several countries

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) has 5 sites in Dél-afrikai Köztársaság and runs in 40 countries. If a site near you is full, another one may still take people.

See A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) in all 40 countries
Építés alatt, nem éles – Áttétes emlőrák: vizsgálatok itt: Dél-afrikai Köztársaság – Frontlight Research